Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast 2025-2034

As per the World Health Organisation (WHO), chronic obstructive pulmonary disease (COPD) ranks as the fourth leading cause of death across the globe, responsible for nearly 5% of all deaths worldwide in 2021. In high-income countries, more than 70% of COPD cases are attributed to tobacco smoking.

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast Report Coverage

The “Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of chronic obstructive pulmonary disease (COPD). It projects the future incidence and prevalence rates of chronic obstructive pulmonary disease (COPD) across various populations. The study covers age, gender, and type as major determinants of the chronic obstructive pulmonary disease (COPD)-affected population. The report highlights patterns in the prevalence of chronic obstructive pulmonary disease (COPD) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of chronic obstructive pulmonary disease (COPD) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Chronic Obstructive Pulmonary Disease (COPD): Disease Overview

Chronic obstructive pulmonary disease (COPD) is a progressive lung condition characterized by restricted airflow and breathing problems. It comprises two main conditions: emphysema, which damages the air sacs in the lungs, and chronic bronchitis, which causes inflammation in the airways. Smoking, long-term exposure to air pollutants, and occupational hazards can increase the risk of developing the disease. Common symptoms include chronic cough, shortness of breath, and wheezing.

Chronic Obstructive Pulmonary Disease (COPD): Treatment Overview

The treatment approach for COPD is focused on managing the symptoms and slowing disease progression. Medications such as bronchodilators help in opening the airways, while steroids reduce inflammation. Combination inhalers, which combine bronchodilators and steroids, are prescribed for effective control of the symptoms. Lifestyle changes, particularly quitting smoking and avoiding respiratory irritants, are recommended for slowing the progression of the disease.

Epidemiology

The chronic obstructive pulmonary disease (COPD) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for chronic obstructive pulmonary disease (COPD) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for chronic obstructive pulmonary disease (COPD) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• In a systematic review and meta-analysis published in the Bulletin of the World Health Organization (2022), the pooled prevalence of chronic obstructive pulmonary disease was estimated to be 11.1%.
• In 2021, chronic obstructive pulmonary disease caused 3.5 million deaths worldwide, accounting for 5% of all global deaths, as per the World Health Organisation (WHO).
• It is estimated that about 90% of COPD deaths in people under 70 years occur in low- and middle-income countries, with 30% to 40% of the cases attributed to tobacco smoking.
• There were about 791,000 emergency department visits in the United States, with COPD as the primary diagnosis, according to the National Hospital Ambulatory Medical Care Survey (2021).

Country-wise Chronic Obstructive Pulmonary Disease (COPD) Epidemiology

The chronic obstructive pulmonary disease (COPD) epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of chronic obstructive pulmonary disease (COPD) varies between countries, owing to differences in factors such as smoking rates, air pollution levels, occupational exposures, healthcare access, socioeconomic status, and public health policies, among others. In 2023, 4.3% of the adult population in the United States were reported to receive a diagnosis of chronic obstructive pulmonary disease, emphysema, or chronic bronchitis.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of chronic obstructive pulmonary disease (COPD) based on several factors.
• Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of Chronic Obstructive pulmonary disease (COPD) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of chronic obstructive pulmonary disease (COPD) epidemiology in the 8 major markets?
• What will be the total number of patients with chronic obstructive pulmonary disease (COPD) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of chronic obstructive pulmonary disease (COPD) in the 8 major markets in the historical period?
• Which country will have the highest number of chronic obstructive pulmonary disease (COPD) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of chronic obstructive pulmonary disease (COPD) during the forecast period of 2025-2034?
• What are the currently available treatments for chronic obstructive pulmonary disease (COPD)?
• What are the disease risks, signs, symptoms, and unmet needs of chronic obstructive pulmonary disease (COPD)?

This product will be delivered within 3-5 business days.